CAPTRUST Financial Advisors
ALXN

CAPTRUST Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,025
Closed -$739K – 4918
2021
Q2 		$739K Sell
4,025
-8,064
-67% -$1.38M 0.01% 839
2021
Q1 		$1.85M Sell
12,089
-21,630
-64% -$3.35M 0.02% 490
2020
Q4 		$5.27M Buy
33,719
+2,571
+8% +$330K 0.07% 233
2020
Q3 		$3.6M Buy
31,148
+4,478
+17% +$483K 0.06% 253
2020
Q2 		$3M Buy
26,670
+24,731
+1,275% +$2.63M 0.05% 289
2020
Q1 		$174K Sell
1,939
-916
-32% -$89.9K ﹤0.01% 915
2019
Q4 		$308K Buy
2,855
+1,970
+223% +$211K ﹤0.01% 834
2019
Q3 		$87K Buy
885
+110
+14% +$12.4K ﹤0.01% 823
2019
Q2 		$102K Buy
775
+64
+9% +$8.25K ﹤0.01% 759
2019
Q1 		$96K Buy
711
+391
+122% +$48.6K ﹤0.01% 715
2018
Q4 		$31K Buy
+320
New +$37.8K ﹤0.01% 895
2018
Q2 		– Sell
-17
Closed -$2K – 1640
2018
Q1 		$2K Buy
+17
New +$2.03K ﹤0.01% 1260

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

CAPTRUST Financial Advisors's ALXN Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,025 shares — an estimated $739K sold.

CAPTRUST Financial Advisors first reported a position in ALXN in Q1 2018 and held it in 12 quarters. The position peaked at $5.27M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 4,025 Alexion Pharmaceuticals shares in Q3 2021, an estimated $739K.
  • CAPTRUST Financial Advisors first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • CAPTRUST Financial Advisors's Alexion Pharmaceuticals position peaked at $5.27M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.